Ocular Therapeutix (FRA:0OT) Shareholder Yield % : -0.10% (As of Mar. 2026)


FRA:0OT Ocular Therapeutix Inc FRA:0OT
51 GF Score
Price €8.25
GF Value €3.75
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Ocular Therapeutix Shareholder Yield %?

Ocular Therapeutix FRA:0OT -1.20% 51 Shareholder Yield % is -0.10% as of Mar. 2026. GuruFocus rates FRA:0OT with a GF Score™ of 51/100 and a GF Value™ of €3.75 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,294 Biotechnology companies, Ocular Therapeutix ranks better than 60.74% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Ocular Therapeutix's Shareholder Yield % was -0.10%.


Ocular Therapeutix  (FRA:0OT) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Ocular Therapeutix Shareholder Yield % Related Terms


Ocular Therapeutix Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Ocular Therapeutix's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocular Therapeutix Shareholder Yield % Chart

Ocular Therapeutix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 -1.57 -25.63 -23.64 -20.71

Ocular Therapeutix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 0.15 -0.01 -20.71 -0.11

FRA:0OT vs NKTR, PVLA, GENB: Shareholder Yield % Comparison

For the Biotechnology subindustry, Ocular Therapeutix's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ocular Therapeutix Shareholder Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Ocular Therapeutix's Shareholder Yield % falls into.


FRA:0OT
51GF Score
Ocular Therapeutix Inc FRA:0OT
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ocular Therapeutix Shareholder Yield % Calculation

Ocular Therapeutix's Shareholder Yield % for the quarter that ended in Mar. 2026 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+0.00 %+0.23 %
=0.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of -0.10% mean?
Ocular Therapeutix (FRA:0OT) has a Shareholder Yield % of -0.10% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Ocular Therapeutix and its competitors. According to the industry distribution chart, Ocular Therapeutix ranks #508 out of 1294 companies in the Biotechnology industry, placing it in the top 39.3%.
Is Ocular Therapeutix's Shareholder Yield % too high?
Ocular Therapeutix's current Shareholder Yield % is -0.10%. Based on the distribution chart, Ocular Therapeutix ranks #508 out of 1294 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ocular Therapeutix has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ocular Therapeutix's Shareholder Yield % compare to NKTR and PVLA?
According to the Biotechnology industry distribution chart, Ocular Therapeutix ranks #508 out of 1294 companies for Shareholder Yield %. This puts Ocular Therapeutix in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Ocular Therapeutix and its competitors. Ocular Therapeutix's current Shareholder Yield % is -0.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocular Therapeutix stock overvalued right now?
Based on GuruFocus' analysis, Ocular Therapeutix (FRA:0OT) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.75, compared to a current price of €8.25 — trading 120% above its estimated fair value. The current Shareholder Yield % is -0.10%. Ocular Therapeutix's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Ocular Therapeutix (FRA:0OT), the current Shareholder Yield % is -0.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ocular Therapeutix (FRA:0OT) Overvalued in 2026?

Based on GuruFocus' analysis, Ocular Therapeutix stock appears to be overvalued. The current stock price of €8.25 is trading 120% above its estimated GF Value™ of €3.75. GuruFocus considers Ocular Therapeutix to be Significantly Overvalued.

Key valuation signals for FRA:0OT:

  • Shareholder Yield %: -0.10%
  • GF Value™: €3.75 vs. price of €8.25 (120% above fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the FRA:0OT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ocular Therapeutix Business Description

Other Exchanges OCUL:USA0OT:Germany
Address 15 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
51GF Score

Get the complete analysis for FRA:0OT

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.25
Price
€3.75
GF Value